Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)
© 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association..
The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Annals of clinical and translational neurology - 10(2023), 4 vom: 09. Apr., Seite 664-667 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lotan, Itay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 26.10.2023 Date Revised 26.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/acn3.51750 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM353588091 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM353588091 | ||
| 003 | DE-627 | ||
| 005 | 20231226060341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/acn3.51750 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1178.xml |
| 035 | |a (DE-627)NLM353588091 | ||
| 035 | |a (NLM)36852731 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lotan, Itay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2023 | ||
| 500 | |a Date Revised 26.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. | ||
| 520 | |a The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of a 95% confidence interval of the crude mortality rate in the cohort to be 2.1%. These data suggest that mortality in MOGAD is lower than that reported in other neuroinflammatory diseases and comparable to the age-adjusted mortality rates of the general population in the United States. Additional studies are warranted to confirm this observation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 700 | 1 | |a Romanow, Gabriela |e verfasserin |4 aut | |
| 700 | 1 | |a Salky, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Molazadeh, Negar |e verfasserin |4 aut | |
| 700 | 1 | |a Vishnevetsky, Anastasia |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Bilodeau, Philippe Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Cutter, Gary |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Michael |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of clinical and translational neurology |d 2014 |g 10(2023), 4 vom: 09. Apr., Seite 664-667 |w (DE-627)NLM234874031 |x 2328-9503 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:4 |g day:09 |g month:04 |g pages:664-667 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/acn3.51750 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 4 |b 09 |c 04 |h 664-667 | ||